Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology, Inc. reported that President & CEO Dennis M. Lanfear received multiple stock option grants covering a total of 3,205,000 shares of common stock at an exercise price of $1.59 per share. These new options replace an equal number of older options with exercise prices ranging from $5.44 to $18.33, which were disposed of back to the company.
Stockholders approved this option repricing on May 29, 2026, and the repricing is conditioned on Lanfear remaining in service through May 29, 2027. One block of options vests in 1/48th monthly installments measured from January 5, 2023, while another block is fully vested and exercisable, aligning his compensation structure more closely with the current share price.
Coherus Oncology, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class III directors Dennis M. Lanfear and Mats L. Wahlström to serve until the 2029 annual meeting. At the record date on April 16, 2026 there were 154,217,609 common shares outstanding, each entitled to one vote.
Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved a non-binding Say-on-Pay resolution for executive compensation. They also approved a reduction in the exercise price of certain outstanding stock options and an increase in the shares reserved under the Amended and Restated 2014 Equity Incentive Award Plan, both equity-related items that can affect future dilution and employee incentives.
Coherus Oncology, Inc. reporting person Timothy G. Youngquist 2020 Irrevocable Trust amended its Schedule 13G to state it beneficially owns 12,750,800 shares of common stock, representing 8.3% of the class based on April 16, 2026 outstanding shares. The filing notes inclusion of 460,000 shares issuable under call options exercisable within 60 days for purposes of Rule 13d-3. The amendment (No. 2) corrects information in a prior amendment and is signed by the trust's manager on May 15, 2026.
Coherus Oncology reported first-quarter 2026 net revenue of $12.3 million, up from $7.6 million a year earlier, driven mainly by LOQTORZI sales of $11.8 million. Gross margin from continuing operations improved to 69%, reflecting higher oncology volume.
The company still posted a net loss of $38.3 million versus $56.6 million in 2025, with continuing operations accounting for a $36.9 million loss. Coherus strengthened liquidity through a February 2026 equity offering, raising $53.6 million net and ending the quarter with $167.0 million in cash, cash equivalents and marketable securities.
Coherus Oncology reported first quarter 2026 results showing early progress in its oncology transition. Net revenue from continuing operations was $12.3 million, up from $7.6 million a year earlier, driven by LOQTORZI net revenue of $11.8 million in the quarter.
GAAP net loss from continuing operations narrowed to $36.9 million, or $(0.27) per share, versus $47.4 million, or $(0.41) per share, with lower R&D and SG&A reflecting the 2025 exit from the biosimilar business. Non-GAAP net loss from continuing operations was $33.9 million, or $(0.25) per share. Cash, cash equivalents and marketable securities totaled $167.0 million as of March 31, 2026, while the company highlighted clinical progress for tagmokitug and casdozokitug alongside its LOQTORZI commercial ramp.
Coherus Oncology, Inc. Schedule 13G/A amendment shows the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 12,790,800 shares of common stock, representing 8.267% of the class. The filing states this percentage is based on 154,217,609 shares outstanding as of April 16, 2026 and includes 500,000 shares underlying call options deemed outstanding for purposes of Rule 13d-3.
Coherus Oncology, Inc. ownership update: Thomas A. Satterfield, Jr. reports beneficial ownership of 6,930,000 shares, equal to 4.6% of the company's common stock. The filing cites 149,889,902 shares outstanding as of February 28, 2026 per the issuer's Form 10-K. The reported holdings combine sole and shared voting/dispositive power and include shares held jointly, by related entities (Tomsat Investment & Trading Co., Inc.; Caldwell Mill Opportunity Fund; A.G. Family L.P.) and multiple limited powers of attorney for other holders.
Coherus Oncology, Inc. amendment to a Schedule 13G/A reports that BlackRock, Inc. beneficially owned 7,337,261 shares of Common Stock, representing 4.9% of the class. The filing lists sole voting power of 7,232,734 shares and sole dispositive power of 7,337,261. The form is signed by a BlackRock Managing Director on 04/27/2026.
Coherus Oncology, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, executive pay, a one-time stock option repricing and a larger equity incentive pool. Holders of 154,217,609 common shares as of April 16, 2026 may vote online or by proxy.
Stockholders will elect two Class III directors, ratify Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on named executive officer compensation. They are also being asked to approve reducing the exercise price and extending the term of 9,540,140 underwater employee and consultant options, and to add 7,700,000 shares to the Amended and Restated 2014 Equity Incentive Award Plan.
The board, which is majority independent and organized into audit, compensation, and nominating/governance committees, recommends voting “FOR” all five proposals, including the equity plan amendment intended to preserve stock‑based incentives as a core element of compensation and retention.